Immunotherapy for Biliary Tract Cancer in the Era of Precision Medicine: Current Knowledge and Future Perspectives
出版年份 2022 全文链接
标题
Immunotherapy for Biliary Tract Cancer in the Era of Precision Medicine: Current Knowledge and Future Perspectives
作者
关键词
-
出版物
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
Volume 23, Issue 2, Pages 820
出版商
MDPI AG
发表日期
2022-01-13
DOI
10.3390/ijms23020820
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Immunotherapies in clinical development for biliary tract cancer
- (2021) Arndt Vogel et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Targeting FGFR inhibition in cholangiocarcinoma
- (2021) Lipika Goyal et al. CANCER TREATMENT REVIEWS
- Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma
- (2021) Robert Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Practical considerations in screening for genetic alterations in cholangiocarcinoma
- (2021) T.S. Bekaii-Saab et al. ANNALS OF ONCOLOGY
- Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial
- (2021) Angela Lamarca et al. LANCET ONCOLOGY
- Assessment of Pembrolizumab Therapy for the Treatment of Microsatellite Instability–High Gastric or Gastroesophageal Junction Cancer Among Patients in the KEYNOTE-059, KEYNOTE-061, and KEYNOTE-062 Clinical Trials
- (2021) Joseph Chao et al. JAMA Oncology
- Immunotherapy in Advanced Biliary Tract Cancers
- (2021) Alice Boilève et al. Cancers
- Camrelizumab plus oxaliplatin‐based chemotherapy as first‐line therapy for advanced biliary tract cancer: A multicenter, phase 2 trial
- (2021) Xinni Chen et al. INTERNATIONAL JOURNAL OF CANCER
- Toripalimab with chemotherapy as first-line treatment for advanced biliary tract tumors: Update analytic results of an open-label phase II clinical study (JS001-ZS-BC001).
- (2021) Wei Li et al. JOURNAL OF CLINICAL ONCOLOGY
- Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2a, multiple basket study
- (2021) Milind Javle et al. LANCET ONCOLOGY
- Cancer Biomarkers in the era of precision oncology: Addressing the needs of patients and health systems
- (2021) Nicola Normanno et al. SEMINARS IN CANCER BIOLOGY
- Final Overall Survival Efficacy Results of Ivosidenib for Patients With Advanced Cholangiocarcinoma With IDH1 Mutation
- (2021) Andrew X. Zhu et al. JAMA Oncology
- How Immunotherapy Has Changed the Continuum of Care in Hepatocellular Carcinoma
- (2021) Giulia Martini et al. Cancers
- Intrahepatic Cholangiocarcinoma: A Summative Review of Biomarkers and Targeted Therapies
- (2021) Alexandra W. Acher et al. Cancers
- Global incidence of and trends in intrahepatic and extrahepatic cholangiocarcinoma from 1993 to 2012
- (2020) Andrea A. Florio et al. CANCER
- Microsatellite instability: a review of what the oncologist should know
- (2020) Kai Li et al. Cancer Cell International
- Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials
- (2020) David S Hong et al. LANCET ONCOLOGY
- Molecular profiling for precision cancer therapies
- (2020) Eoghan R. Malone et al. Genome Medicine
- Trial watch: chemotherapy-induced immunogenic cell death in immuno-oncology
- (2020) Isaure Vanmeerbeek et al. OncoImmunology
- Efficacy and safety of pembrolizumab for the treatment of advanced biliary cancer: Results from the KEYNOTE-158 and KEYNOTE-028 studies
- (2020) Sarina A. Piha-Paul et al. INTERNATIONAL JOURNAL OF CANCER
- Phase II study assessing tolerability, efficacy, and biomarkers for durvalumab (D) ± tremelimumab (T) and gemcitabine/cisplatin (GemCis) in chemo-naïve advanced biliary tract cancer (aBTC).
- (2020) Do-Youn Oh et al. JOURNAL OF CLINICAL ONCOLOGY
- Final results from the phase I study expansion cohort of the selective FGFR inhibitor Debio 1,347 in patients with solid tumors harboring an FGFR gene fusion.
- (2020) James M. Cleary et al. JOURNAL OF CLINICAL ONCOLOGY
- FOENIX-CCA2: A phase II, open-label, multicenter study of futibatinib in patients (pts) with intrahepatic cholangiocarcinoma (iCCA) harboring FGFR2 gene fusions or other rearrangements.
- (2020) Lipika Goyal et al. JOURNAL OF CLINICAL ONCOLOGY
- Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study
- (2020) Ghassan K Abou-Alfa et al. LANCET ONCOLOGY
- Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study
- (2020) Ghassan K Abou-Alfa et al. LANCET ONCOLOGY
- Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma
- (2020) Richard S. Finn et al. NEW ENGLAND JOURNAL OF MEDICINE
- PD-1/PD-L1 Based Combinational Cancer Therapy: Icing on the Cake
- (2020) Jian-ye Zhang et al. Frontiers in Pharmacology
- A Phase 2 Multi-institutional Study of Nivolumab for Patients With Advanced Refractory Biliary Tract Cancer
- (2020) Richard D. Kim et al. JAMA Oncology
- Phase I study of bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in patients with pretreated biliary tract cancer
- (2020) Changhoon Yoo et al. Journal for ImmunoTherapy of Cancer
- Biliary Tract Cancer: Current Medical Treatment Strategies
- (2020) Ester Oneda et al. Cancers
- Clinical development of therapies targeting TGFβ: current knowledge and future perspectives.
- (2020) D. Ciardiello et al. ANNALS OF ONCOLOGY
- Phase 1, First-in-Human Study of Futibatinib, a Highly Selective, Irreversible FGFR1–4 Inhibitor in Patients with Advanced Solid Tumors
- (2020) R. Bahleda et al. ANNALS OF ONCOLOGY
- Review of precision cancer medicine: Evolution of the treatment paradigm
- (2020) Apostolia M. Tsimberidou et al. CANCER TREATMENT REVIEWS
- FIGHT-302: first-line pemigatinib vs gemcitabine plus cisplatin for advanced cholangiocarcinoma with FGFR2 rearrangements
- (2020) Tanios S Bekaii-Saab et al. Future Oncology
- Infigratinib in patients with advanced cholangiocarcinoma with FGFR2 gene fusions/translocations: the PROOF 301 trial
- (2020) Shalini Makawita et al. Future Oncology
- The Tumor Microenvironment in Cholangiocarcinoma Progression
- (2020) Luca Fabris et al. HEPATOLOGY
- A decade of immune-checkpoint inhibitors in cancer therapy
- (2020) Caroline Robert Nature Communications
- Evaluation of Combination Nivolumab and Ipilimumab Immunotherapy in Patients With Advanced Biliary Tract Cancers
- (2020) Oliver Klein et al. JAMA Oncology
- Efficacy and biomarker analysis of nivolumab plus gemcitabine and cisplatin in patients with unresectable or metastatic biliary tract cancers: results from a phase II study
- (2020) Kaichao Feng et al. Journal for ImmunoTherapy of Cancer
- Targeted Therapies in Advanced Biliary Tract Cancer: An Evolving Paradigm
- (2020) Sakti Chakrabarti et al. Cancers
- Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study
- (2020) Aurélien Marabelle et al. LANCET ONCOLOGY
- Dabrafenib plus trametinib in patients with BRAFV600E-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial
- (2020) Vivek Subbiah et al. LANCET ONCOLOGY
- Clinical Activity and Safety of the Anti–Programmed Death 1 Monoclonal Antibody Dostarlimab for Patients With Recurrent or Advanced Mismatch Repair–Deficient Endometrial Cancer
- (2020) Ana Oaknin et al. JAMA Oncology
- Triplet combination of durvalumab, tremelimumab, and paclitaxel in biliary tract carcinomas: Safety run-in results of the randomized IMMUNOBIL PRODIGE 57 phase II trial
- (2020) Alice Boilève et al. EUROPEAN JOURNAL OF CANCER
- Pembrolizumab in Microsatellite-Instability–High Advanced Colorectal Cancer
- (2020) Thierry André et al. NEW ENGLAND JOURNAL OF MEDICINE
- Clinicogenomic Analysis of FGFR2-Rearranged Cholangiocarcinoma Identifies Correlates of Response and Mechanisms of Resistance to Pemigatinib
- (2020) Ian M. Silverman et al. Cancer Discovery
- Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
- (2019) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
- (2019) Brian I. Rini et al. NEW ENGLAND JOURNAL OF MEDICINE
- The Tumor Microenvironment and Immune Milieu of Cholangiocarcinoma
- (2019) Luca Fabris et al. LIVER INTERNATIONAL
- Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study
- (2019) John N Primrose et al. LANCET ONCOLOGY
- Evaluation of safety and tolerability of durvalumab (D) with or without tremelimumab (T) in patients (pts) with biliary tract cancer (BTC).
- (2019) Tatsuya Ioka et al. JOURNAL OF CLINICAL ONCOLOGY
- A Phase I, Open-Label, Multicenter, Dose-escalation Study of the Oral Selective FGFR Inhibitor Debio 1347 in Patients with Advanced Solid Tumors Harboring FGFR Gene Alterations
- (2019) Martin H. Voss et al. CLINICAL CANCER RESEARCH
- FDA Approval Summary: Pembrolizumab for the treatment of microsatellite instability-high solid tumors
- (2019) Leigh Marcus et al. CLINICAL CANCER RESEARCH
- Updated results of a phase IIa study to evaluate the clinical efficacy and safety of erdafitinib in Asian advanced cholangiocarcinoma (CCA) patients with FGFR alterations.
- (2019) Joon Oh Park et al. JOURNAL OF CLINICAL ONCOLOGY
- Immunotherapy of colorectal cancer: Challenges for therapeutic efficacy
- (2019) Davide Ciardiello et al. CANCER TREATMENT REVIEWS
- Ramucirumab plus pembrolizumab in patients with previously treated advanced non-small-cell lung cancer, gastro-oesophageal cancer, or urothelial carcinomas (JVDF): a multicohort, non-randomised, open-label, phase 1a/b trial
- (2019) Roy S Herbst et al. LANCET ONCOLOGY
- Nivolumab alone or in combination with cisplatin plus gemcitabine in Japanese patients with unresectable or recurrent biliary tract cancer: a non-randomised, multicentre, open-label, phase 1 study
- (2019) Makoto Ueno et al. Lancet Gastroenterology & Hepatology
- 1272PLenvatinib plus PD-1 blockade in advanced bile tract carcinoma
- (2019) J Lin et al. ANNALS OF ONCOLOGY
- Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair–Deficient Cancer: Results From the Phase II KEYNOTE-158 Study
- (2019) Aurelien Marabelle et al. JOURNAL OF CLINICAL ONCOLOGY
- Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial
- (2019) Robert J Motzer et al. LANCET ONCOLOGY
- Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1–2 trials
- (2019) Robert C Doebele et al. LANCET ONCOLOGY
- Tumor Angiogenesis and Anti-Angiogenic Strategies for Cancer Treatment
- (2019) Raluca Ioana Teleanu et al. Journal of Clinical Medicine
- O-001Efficacy of TAS-120, an irreversible fibroblast growth factor receptor (FGFR) inhibitor, in cholangiocarcinoma patients with FGFR pathway alterations who were previously treated with chemotherapy and other FGFR inhibitors
- (2018) F Meric-Bernstam et al. ANNALS OF ONCOLOGY
- Comprehensive molecular profiling of intra- and extrahepatic cholangiocarcinomas: potential targets for intervention
- (2018) Maeve A Lowery et al. CLINICAL CANCER RESEARCH
- Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair–Deficient/Microsatellite Instability–High Metastatic Colorectal Cancer
- (2018) Michael J. Overman et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II Study of BGJ398 in Patients With FGFR-Altered Advanced Cholangiocarcinoma
- (2018) Milind Javle et al. JOURNAL OF CLINICAL ONCOLOGY
- Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children
- (2018) Alexander Drilon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ramucirumab Plus Pembrolizumab in Patients with Previously Treated Advanced or Metastatic Biliary Tract Cancer: Nonrandomized, Open‐Label, Phase I Trial (JVDF)
- (2018) Hendrik‐Tobias Arkenau et al. ONCOLOGIST
- Immunogenic cell death in anticancer chemotherapy and its impact on clinical studies
- (2018) Qiang Wang et al. CANCER LETTERS
- Fundamental Mechanisms of Immune Checkpoint Blockade Therapy
- (2018) Spencer C. Wei et al. Cancer Discovery
- Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic
- (2018) T A Chan et al. ANNALS OF ONCOLOGY
- Derazantinib (ARQ 087) in advanced or inoperable FGFR2 gene fusion-positive intrahepatic cholangiocarcinoma
- (2018) Vincenzo Mazzaferro et al. BRITISH JOURNAL OF CANCER
- Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial
- (2018) Frank Stephen Hodi et al. LANCET ONCOLOGY
- Whole-Genome and Epigenomic Landscapes of Etiologically Distinct Subtypes of Cholangiocarcinoma
- (2017) Apinya Jusakul et al. Cancer Discovery
- Cancer Immunotherapy: Historical Perspective of a Clinical Revolution and Emerging Preclinical Animal Models
- (2017) William K. Decker et al. Frontiers in Immunology
- Immunological Effects of Conventional Chemotherapy and Targeted Anticancer Agents
- (2015) Lorenzo Galluzzi et al. CANCER CELL
- PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy
- (2015) S. P. Patel et al. MOLECULAR CANCER THERAPEUTICS
- Genomic spectra of biliary tract cancer
- (2015) Hiromi Nakamura et al. NATURE GENETICS
- Radiotherapy and Immunogenic Cell Death
- (2015) Encouse B. Golden et al. SEMINARS IN RADIATION ONCOLOGY
- The Microsatellite Instable Subset of Colorectal Cancer Is a Particularly Good Candidate for Checkpoint Blockade Immunotherapy
- (2015) Yanping Xiao et al. Cancer Discovery
- Anti-angiogenic therapy for cancer: current progress, unresolved questions and future directions
- (2014) Naveen S. Vasudev et al. ANGIOGENESIS
- Cisplatin-Induced Antitumor Immunomodulation: A Review of Preclinical and Clinical Evidence
- (2014) A. R. de Biasi et al. CLINICAL CANCER RESEARCH
- Fibroblast growth factor receptor 2 translocations in intrahepatic cholangiocarcinoma
- (2014) Rondell P. Graham et al. HUMAN PATHOLOGY
- Treatment and Prognosis for Patients With Intrahepatic Cholangiocarcinoma
- (2014) Michael N. Mavros et al. JAMA Surgery
- Defining the Molecular Signature of Chemotherapy-Mediated Lung Tumor Phenotype Modulation and Increased Susceptibility to T-Cell Killing
- (2012) Sofia R. Gameiro et al. CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS
- Epithelial-Mesenchymal Transition Induced by Transforming Growth Factor-β1/Snail Activation Aggravates Invasive Growth of Cholangiocarcinoma
- (2010) Yasunori Sato et al. AMERICAN JOURNAL OF PATHOLOGY
- Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer
- (2010) Juan Valle et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pre-treatment with chemotherapy can enhance the antigenicity and immunogenicity of tumours by promoting adaptive immune responses
- (2009) W M Liu et al. BRITISH JOURNAL OF CANCER
- Epidemiology of biliary tract cancers: an update
- (2008) G. Randi et al. ANNALS OF ONCOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started